Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin.

Patients with type 2 diabetes (T2D) who had been using insulin an average of 8 years and had mean glycated hemoglobin (A1C) levels of 8.9% were able to bring their levels down 0.9% after 3 months, ...

(RTTNews) - Abbott Laboratories {ABT) said that new data showed its continuous glucose monitoring technology, FreeStyle Libre System, significantly reduced HbA1C levels in people with type 2 diabetes ...

The real world data, mostly of European users, spans two years and includes data from 50,000 readers and 285,000 sensors . It represents 86.4 million monitoring hours and 63.8 million distinct scans.

Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...

ABBOTT PARK, Ill., June 16, 2020 — Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading 3 sensor-based glucose monitoring technology, is ...

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

In its first evaluation of real-world data derived from its FreeStyle Libre continuous glucose monitor in people with Type 2 diabetes, Abbott found that the system was able to significantly reduce ...

ABBOTT PARK, Ill., June 13, 2020 /PRNewswire/ -- Today, Abbott (NYSE: ABT) announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading 3 continuous glucose ...